Effect of Activated Vitamin D on Glucoparameters in HCV Seropositive and Seronegative Patients on Chronic Hemodialysis

Ibrahim, Mohamed A.; Sany, Dawlat; Shahawy, Yasser El; Awdallah, A.

doi:10.3109/0886022x.2012.706877

Cited by 3 publications

(8 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 12 studies were NRIS that also reported a control group of healthy volunteers who served as comparison for demonstrating improvement from baseline values in the HD group after vitamin D treatment. [11, 12, 21, 22, 24–27, 29, 30, 32, 33]…”

Section: Resultsmentioning

confidence: 99%

“…Diabetic patients were included in 3 studies. [14, 30, 32] The mean BMI reported in 4 studies was between 20.6 to 34.6 kg/m 2 . [14, 27, 29, 33] Body weight was reported as within 115–120% of ideal weight for height.…”

Section: Resultsmentioning

confidence: 99%

“…Participants in Ulutas 2013 study continued to take 1-α-calciferol for secondary hyperparathyroidism along with the intervention. [33] Other studies had protocols where participants stopped taking vitamin D supplements 2 to 4 weeks prior to the start of the study[11–13, 26, 32]; or were never on vitamin D supplementation. [22, 31] Of note, in the two Mak 1992 studies, participants discontinued oral calcitriol only 3 days prior to study intervention.…”

Section: Resultsmentioning

confidence: 99%

“…Improved hemoglobin A1C (HbA1C%) values were also observed (Tables 3 and 4). [21, 23, 31, 32] There was greater evidence for improvement of glucose-stimulated insulin secretion based on hyperglycemic clamp testing or glucose tolerance testing (Table 4). [11, 12, 23–26] Similar results were obtained with testing for HOMA-IR, except in the Hung 2012 study (Tables 3 and 4).…”

Section: Resultsmentioning

confidence: 99%

“…Firstly, outcomes varied by definition and measurement, only a few studies measured outcomes of interest such as HOMA-IR. [14, 31, 32] Hyperglycemia and glucose intolerance only manifest at later stages of insulin resistance when it cannot be overcome by insulin secretion. [4] Hyperinsulinemic euglycemic clamp studies and intravenous glucose tolerance tests are cumbersome and were infrequently conducted, though they are the gold standard test for insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

Purpose We tested whether short-term vitamin D supplementation improves insulin resistance in patients with kidney disease, a condition with little intrinsic vitamin D activity. Methods PubMed, Embase and CENTRAL were searched for relevant observational studies and randomized clinical trials (RCTs). Random effects models were employed for meta-analysis and effect sizes were summarized as standardized mean difference (SMD) with 95% confidence intervals. Separate analyses were done for RCTs and non-randomized intervention studies (NRIS). Results Seventeen studies (5 RCTs and 12 NRIS) were included. The meta-analysis population (n=131) was mostly middle aged (40–50 years), male and non-diabetic, and on hemodialysis. The duration (4–12 weeks) and type of supplementation varied between studies. Among RCTs, compared to placebo, vitamin D supplementation was associated with significant decrease in fasting glucose [SMD −1.13,( −2.11 to −0.11)] and PTH levels [SMD −1.50,(−2.95 to −0.04)] but no difference in fasting insulin levels [SMD 1.32, (−0.15 to 2.79). Among NRIS, there was only a significant decrease in PTH levels [SMD −1.68, (−2.55 to −0.82)] between pre and post-vitamin D treatment levels. Conclusions Short term (4–12 weeks) supplementation with vitamin D is associated with lower fasting glucose levels in ESRD with no change in fasting insulin levels. However, the findings from this study are limited by the studies that were used in the meta-analysis, which were mostly small, used multiple different vitamin D compounds and dosing regimens, had large heterogeneity and funnel plots showed there was a dearth of studies with null or negative finding. Therefore, larger randomized clinical trials need to be performed to answer this important clinical question.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

Study of the effect of vitamin D supplementation on glycemic control in type 2 diabetic prevalent hemodialysis patients

Ibrahim

Sarhan

Halawa

et al. 2015

Hemodialysis International

View full text Add to dashboard Cite

Vitamin D is claimed to have an adjuvant effect on glycemic control by dual action on pancreatic β-cells and insulin resistance. The aim of this study was to assess the possible effect of short-term alfacalcidol supply on glycemic control in type 2 diabetic hemodialysis (HD) patients. Twenty type 2 diabetic HD patients (using diet and oral drugs but not insulin) were randomly selected from our dialysis unit as well as 20 non-diabetic HD patients as control. A third group of 12 healthy subjects were studied as well. All three groups were similar in age, sex, and body mass index. Oral alfacalcidol therapy was administrated daily as recommended by Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for 12 weeks guided by monthly serum phosphorus and Cax PO4 product. Corrected total calcium, phosphorus, intact parathyroid hormone, 25-hydroxy vitamin D (25[OH]D), and glucoparameters (fasting blood glucose, glycated hemoglobin [HbA1c%], insulin resistance by homeostatic model assessment, and β-cell function by HOMA-β%) were measured under basal conditions and after 3 months of therapy. 25(OH)D was non-significantly lower in diabetic than non-diabetic HD patients, but significantly lower than healthy subjects at the start of the study. However, vitamin D level increased significantly after 3 months of trial, although the levels did not reach normal values. This vitamin D rise was associated with highly significant improvement in concentrations of fasting blood sugar (FBS), fasting insulin, HbA1c%, and HOMA-β-cell function in diabetic and non-diabetic controls. However, there was a significant rise in insulin resistance after treatment. The percentage of change was evident more in diabetics regarding FBS and 25(OH)D concentration. Adjustment of 25(OH)D level in type 2 diabetic prevalent HD patients may improve, at least with short-term therapy, glycemic control mainly through improving β-cell function.

show abstract

Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications

Gurunathan

Lee

Kim

2022

IJMS

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that has caused a ‘coronavirus disease 2019’ (COVID-19) pandemic in multiple waves, which threatens human health and public safety. During this pandemic, some patients with COVID-19 acquired secondary infections, such as mucormycosis, also known as black fungus disease. Mucormycosis is a serious, acute, and deadly fungal infection caused by Mucorales-related fungal species, and it spreads rapidly. Hence, prompt diagnosis and treatment are necessary to avoid high mortality and morbidity rates. Major risk factors for this disease include uncontrolled diabetes mellitus and immunosuppression that can also facilitate increases in mucormycosis infections. The extensive use of steroids to prevent the worsening of COVID-19 can lead to black fungus infection. Generally, antifungal agents dedicated to medical applications must be biocompatible, non-toxic, easily soluble, efficient, and hypoallergenic. They should also provide long-term protection against fungal growth. COVID-19-related black fungus infection causes a severe increase in fatalities. Therefore, there is a strong need for the development of novel and efficient antimicrobial agents. Recently, nanoparticle-containing products available in the market have been used as antimicrobial agents to prevent bacterial growth, but little is known about their efficacy with respect to preventing fungal growth, especially black fungus. The present review focuses on the effect of various types of metal nanoparticles, specifically those containing silver, zinc oxide, gold, copper, titanium, magnetic, iron, and carbon, on the growth of various types of fungi. We particularly focused on how these nanoparticles can impact the growth of black fungus. We also discussed black fungus co-infection in the context of the global COVID-19 outbreak, and management and guidelines to help control COVID-19-associated black fungus infection. Finally, this review aimed to elucidate the relationship between COVID-19 and mucormycosis.

show abstract

Effect of Activated Vitamin D on Glucoparameters in HCV Seropositive and Seronegative Patients on Chronic Hemodialysis

Cited by 3 publications

References 52 publications

The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

Study of the effect of vitamin D supplementation on glycemic control in type 2 diabetic prevalent hemodialysis patients

Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications

Contact Info

Product

Resources

About